Good news has been scarce for this beaten-down drugmaker.

Pfizer Inc. (NYSE:PFE) is one of the best undervalued stocks under $50 to invest in now. Pfizer Inc. (NYSE:PFE) announced on ...

Bristol Myers SquibbBMY recently won FDA and European Commission (EC) approvals for the label expansion of its blockbuster ...

Shares of C4 Therapeutics rose after the company dosed its first patient in a Phase 1b trial for a multiple myeloma treatment. Shares were up 6.6% to $2.67 in Wednesday afternoon trading. The stock is ...

It’s rare to get such a massive high-yielder that’s also positioning itself for long-term growth. Of course, shares of Pfizer ...

Ireland Day at the NYSE signalled a new, more strategic phase in US-Ireland economic ties, from AI investment to defence.

Pfizer has quietly built momentum in 2026 and Guggenheim just raised its price target to $36 while reiterating a Buy rating.

Pfizer (PFE +1.26%) stock hasn't made for a good investment over the past five years. It has declined by 25% in value over ...

The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.

Pfizer wants to fill a 20-year void in human Lyme disease vaccines, but must win over regulators under a vaccine-skeptical ...

An experimental vaccine for Lyme disease is broadly effective, pharmaceutical companies Pfizer and Valneva announced Monday, ...

Pfizer and its partner plan to seek regulatory approval for a Lyme disease vaccine. Pharmaceutical giant Pfizer and French ...